Aposense seeks to raise $20M from IPO

05/17/2010 | Globes (Israel)

Aposense hopes to raise $20 million from an initial public offering. The company is working to develop personalized drugs for oncology, cardiology and neurology using its programmed cell death technology. Its first major product is its molecular imaging agent for brain cancer, which currently is in a Phase II study and expected to be on the market by 2012.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR